A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for
patients with incurable, refractory germ cell tumors. Patients will be treated until evidence
of disease progression, non-compliance with study protocol, unacceptable major toxicity, at
subject's own request for withdrawal, or if the study closes for any reason.